Aims To evaluate initial blood pressure effects of the angiotensin II antagonist losartan (L) immediately after switching from an ACE inhibitor (captopril, C). Methods Two-phase multicentre randomized study in 177 outpatients with mild to moderate essential hypertension. For 6 weeks all patients received 25 mg C twice daily. Then they were randomized double-blind to switch for another 6 weeks to 50 mg L once daily (n=110) or to maintain C (n=55). On the first day of the switch they underwent ambulatory blood pressure measurement (ABPM).
Patients had to have at least two documented sitting blood Introduction pressure measurements above 160 mm Hg systolic and 95 mmHg diastolic (diastolic maximum: 115 mmHg) during Angiotensin II AT1-subtype receptor antagonists are a new class of antihypertensive agents of which losartan (L) is the the screening period. Renal function had to be normal (blood urea <12.5 mmol l −1
and serum creatinine first and most extensively studied compound [1, 2] . ACE inhibitors, in addition to reducing the production <150 mmol l −1 ). Patients with heart failure or any other clinically significant cardiopulmonary, hepatic, metabolic or of angiotensin II, may lead to accumulation of vasodilatory kinins by inhibiting the enzyme kininase II and might neurological disorders, with drug-or alcohol abuse or with any contraindication to AII antagonists or ACE inhibitors therefore have an additional hypotensive effect.
After an initial dose of ACE inhibitors or angiotensin II were excluded. The most common concomitant diagnoses were lipid disorders (41%), diabetes mellitus (22%) and antagonists symptomatic hypotensive episodes have been observed when the RAAS had been stimulated by hyperuricaemia (16%). sodium/water deficiency [3, 4] , diuretic pretreatment or by diseases such as heart failure [5] . The study protocol including the informed consent form
Study design
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had been reviewed and approved locally by the ethical review boards responsible for each single centre. It was blind therapy. A fall of systolic BP >30 mmHg (or <100 mmHg), was experienced in 31% (3%) of patients conducted and monitored according to the European Guidelines for Good Clinical Practice (GCP).
who switched to losartan compared with 24% (6%) of patients continuing with captopril ( Table 1 ). The relative risk of such asymptomatic initial hypotensive episodes after Blood pressure measurement techniques switching from C to L compared with staying with C was 1.01 (95% confidence interval: 0.63 to 1.75 ). An automatic 24 h oscillometric monitor (Spacelabs) was used. The measurement intervals were 15 min during the Figure 1 compares the two 24 h ABPM profiles of the first day of double-blind therapy. While captopril showed a day and 30 min at night (22.00 h-06.00 h).
Patients underwent a first 24 h ambulatory blood pressure trend towards an earlier peak effect, there were no significant differences in the course of the curves. Especially there was monitoring (ABPM) during the captopril phase and a second 24 h ABPM at the first day of the double-blind phase. This no decrease in BP within the first 12 h exceeding the normal circadian rhythm. second 24 h ABPM measurement period began 12 h after the last dose of captopril, with the first double-blind dose, either losartan 50 mg (switch arm) or with continuation of Tolerability and adverse events the morning dose captopril 25 mg (maintained arm).
No clinical symptoms of hypotension were recorded during the starting day of the double-blind treatment period.
Statistics
Within the open baseline phase of 6 weeks, when all 177 patients received 25 mg captopril twice daily, 25 (14%) The incidence of initial symptomatic hypotension following the first dose of an ACE-inhibitor in hypertensive patients patients reported at least one clinical adverse event (AE). During the 6 week double-blind phase at least one AE is reported between 0.7 and 10% depending on definition and type of study [12] . The purpose of this trial was to was reported by 9% in the losartan group and by 16% in the captopril group. The relative risk of experiencing any document the incidence of asymptomatic hypotension as determined by 24 h blood pressure monitoring. The study clinical adverse experience in the 6 weeks after switch from captopril to losartan, compared to staying on captopril for was powered to detect overshooting reductions in systolic blood pressure with an incidence of at least 15% in the another 6 weeks, was 0.56 (95% confidence interval: 0.25 to 1.26). None of the AEs was serious. losartan group with 95% probability. Such episodes were defined as:
Headache (in 3% of patients with losartan and 5% with captopril) was the adverse event most frequently reported. 1. A fall >30 mmHg in systolic BP within 12 h of the first dose (confirmed by two consecutive ABPM readings) or Discussion 2. Two consecutive systolic BP readings <100 mmHg within the first 12 h.
Starting therapy interfering with the renin angiotensin system (RAS), e.g. with ACE inhibitors or angiotensin II Since the study was not designed for comparisons between groups, descriptive statistics are presented as an estimate and antagonists, can result in an initial overshooting blood pressure reduction [12] . Especially after pretreatment with 95% confidence interval of the relative risk of asymptomatic hypotension.
diuretics or during conditions of salt or water deficiency the RAS is stimulated, and first doses of ACE inhibitors should be administered with caution. Angiotensin II antagonists are Results the most specific blockers of the RAS [14, 15] . Thus the question whether angiotensin II receptor blockers can be One hundred and seventy-seven patients were recruited into the baseline phase, of which 165 (63 female and 102 male) safely given after pretreatment with ACE inhibitors is important for clinical medicine. To date only data are were randomized into the double-blind portion of the study. The treatment groups did not significantly differ regarding available evaluating start of therapy with losartan in patients with diuretic pretreatment, where no cases of symptomatic age, gender, secondary diagnoses and severity of hypertension. One hundred and five patients (95%) completed hypotension were described in a study of 230 patients [11] . Peak plasma levels of losartan are reached approximately 1 h losartan treatment and 51 patients (93%) finished the trial on captopril. Due to missing or incomplete ABPM after oral administration. The half-life is approximately 2 h. Losartan is converted in the liver into an active metabolite measurements 21 patients had to be excluded from the analysis of initial hypotension. These patients did not differ EXP 3174, which has a receptor affinity approximately tenfold higher than the parent substance. Peak plasma levels of with respect to demographics or diagnoses from the entire sample. Thus data of 94 patients switching to losartan and EXP 3174 are reached after about 4.5 h; the half-life is approximately 6-9 h [6, 7] . On the basis of these pharmaco-50 patients staying with captopril remained for primary analysis.
kinetic data, an antihypertensive effect with a slow onset lasting over 24 h is expected and has been shown in several clinical studies [8] [9] [10] . Initial hypotensive episodes, particularly with Ambulatory blood pressure measurement after switch of therapy clinical symptoms, are extremely rare [11] . This randomized double-blind study was the first trial ABPM measurement of the first day of the double-blind phase started 12 h after the last intake of captopril 25 mg, designed to evaluate whether there are any clinically meaningful hypotensive first dose reactions if the angiotensin when patients were administered the first dose of double- [12], the study was designed to look for the percentage of patients experiencing any symptomatic or asymptomatic fall of systolic blood pressure (defined as a decrease >30 mmHg or to an absolute value <100 mmHg).
Between the losartan and captopril control group there was no statistically or clinically relevant difference in the number of patients whose systolic blood pressure decreased significantly. No clinical adverse event was seen which could be attributed to a first dose reaction during switch from captopril to losartan.
As in other trials with losartan [9, 10, 16] clinical adverse events were infrequent, generally non-serious and of mild intensity. Despite lacking statistical significance it is noteworthy that switch from captopril to losartan reduced the incidence of experiencing an adverse event by 44% compared with maintaining therapy with the ACE inhibitor.
In summary, in this study the angiotensin II antagonist losartan was effective and generally well tolerated when administered immediately after pretreatment with an ACE inhibitor. 
